Literature DB >> 14609489

The assessment and importance of disease activity versus disease damage in patients with inflammatory myopathy.

Shabina M Sultan1.   

Abstract

To capture the totality of the effect of a disease on a patient, three aspects of the disease need to be assessed: 1) the disease activity (which is potentially reversible with treatment); 2) damage (defined as irreversible changes in anatomy, physiology, or function) accumulated since the onset of the disease, albeit from the disease itself, comorbid conditions, or as a result of therapy; and 3) the patient's perception of the disease, because this is frequently different from the physician's perception. A fine line exists between under-treating a patient, which may lead to an increase in disease activity, and over- treating a patient, with the risk of serious morbidity from inappropriate therapy. Distinguishing between activity and damage can be difficult and measures to ascertain this are discussed. Further developments are underway to assess the measures that should be used for the assessment of disease activity and damage.

Entities:  

Mesh:

Year:  2003        PMID: 14609489     DOI: 10.1007/s11926-003-0055-z

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  25 in total

1.  Validation of the Childhood Health Assessment Questionnaire in the juvenile idiopathic myopathies. Juvenile Dermatomyositis Disease Activity Collaborative Study Group.

Authors:  A M Huber; J E Hicks; P A Lachenbruch; M D Perez; L S Zemel; R M Rennebohm; C A Wallace; C B Lindsley; M H Passo; S H Ballinger; S L Bowyer; A M Reed; P H White; I M Katona; F W Miller; L G Rider; B M Feldman
Journal:  J Rheumatol       Date:  2001-05       Impact factor: 4.666

Review 2.  Assessing patients with lupus: towards a drug responder index.

Authors:  D Isenberg; R Ramsey-Goldman
Journal:  Rheumatology (Oxford)       Date:  1999-11       Impact factor: 7.580

3.  A functional index in myositis.

Authors:  A Josefson; E Romanus; J Carlsson
Journal:  J Rheumatol       Date:  1996-08       Impact factor: 4.666

4.  Interstitial lung disease in polymyositis and dermatomyositis. Clinical features and prognosis as correlated with histologic findings.

Authors:  H D Tazelaar; R W Viggiano; J Pickersgill; T V Colby
Journal:  Am Rev Respir Dis       Date:  1990-03

Review 5.  Muscle imaging in inflammatory myopathies.

Authors:  C D Reimers; M Finkenstaedt
Journal:  Curr Opin Rheumatol       Date:  1997-11       Impact factor: 5.006

6.  Elevation of serum soluble tumour necrosis factor receptors in patients with polymyositis and dermatomyositis.

Authors:  T Shimizu; Y Tomita; K Son; S Nishinarita; S Sawada; T Horie
Journal:  Clin Rheumatol       Date:  2000       Impact factor: 2.980

7.  Elevated serum levels of neopterin in adult patients with polymyositis/dermatomyositis.

Authors:  M Y Samsonov; E L Nassonov; G P Tilz; B M Geht; U Demel; G T Gurkina; V Z Shtutman; A G Guseva; H Wachter; D Fuchs
Journal:  Br J Rheumatol       Date:  1997-06

Review 8.  Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies.

Authors:  F W Miller; L G Rider; Y L Chung; R Cooper; K Danko; V Farewell; I Lundberg; C Morrison; L Oakley; I Oakley; C Pilkington; J Vencovsky; K Vincent; D L Scott; D A Isenberg
Journal:  Rheumatology (Oxford)       Date:  2001-11       Impact factor: 7.580

9.  Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies: I. Physician, parent, and patient global assessments. Juvenile Dermatomyositis Disease Activity Collaborative Study Group.

Authors:  L G Rider; B M Feldman; M D Perez; R M Rennebohm; C B Lindsley; L S Zemel; C A Wallace; S H Ballinger; S L Bowyer; A M Reed; M H Passo; I M Katona; F W Miller; P A Lachenbruch
Journal:  Arthritis Rheum       Date:  1997-11

10.  von Willebrand factor in juvenile dermatomyositis.

Authors:  B J Bloom; L B Tucker; L C Miller; J G Schaller
Journal:  J Rheumatol       Date:  1995-02       Impact factor: 4.666

View more
  3 in total

1.  Manual muscle testing and hand-held dynamometry in people with inflammatory myopathy: An intra- and interrater reliability and validity study.

Authors:  Pierrette Baschung Pfister; Eling D de Bruin; Iris Sterkele; Britta Maurer; Rob A de Bie; Ruud H Knols
Journal:  PLoS One       Date:  2018-03-29       Impact factor: 3.240

2.  Possible predictive formulas for quantitative and time-based estimation of muscle strength during motion.

Authors:  Umi Matsumura; Ayana Kai; Miku Numata; Yeonghee Lee; Shimpei Yamamoto; Toshiya Tsurusaki
Journal:  J Phys Ther Sci       Date:  2020-01-22

3.  Patient insights on living with idiopathic inflammatory myopathy and the limitations of disease activity measurement methods - a qualitative study.

Authors:  Alexander Oldroyd; William Dixon; Hector Chinoy; Kelly Howells
Journal:  BMC Rheumatol       Date:  2020-09-21
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.